We are live on
!
Find out more
CM
Castleark Management Portfolio holdings
AUM
$3.02B
1-Year Est. Return
53.92%
This Fund
S&P 500
This Quarter
Est. Return
+26.27%
1 Year Est. Return
+53.92%
3 Year Est. Return
+208.37%
5 Year Est. Return
+342.22%
10 Year Est. Return
+3,246.09%
AUM
$2.67B
AUM Growth
+$119M
(+4.7%)
Cap. Flow
-$339M
Cap. Flow
% of AUM
-12.7%
Top 10 Holdings %
Top 10 Hldgs %
26.02%
Holding
382
New
39
Increased
53
Reduced
139
Closed
54
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 Value ETF
IWN
|
+$19.7M |
| 2 |
Nike
NKE
|
+$17.4M |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$15M |
| 4 |
Veracyte
VCYT
|
+$11.7M |
| 5 |
Lam Research
LRCX
|
+$8.72M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPDR Gold Trust
GLD
|
+$46.2M |
| 2 |
Apple
AAPL
|
+$22M |
| 3 |
UnitedHealth
UNH
|
+$18.6M |
| 4 |
Enphase Energy
ENPH
|
+$16.1M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$15.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.21% |
| 2 | Healthcare | 16.44% |
| 3 | Consumer Discretionary | 16.08% |
| 4 | Financials | 8.79% |
| 5 | Industrials | 8.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BHVN
126
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $5.8M | 0.22% |
67,716
-60,245
| -47% | -$5.11M |
|
127
MongoDB
MDB
$25.8B
| $5.71M | 0.21% |
15,914
-3,290
| -17% | -$919K |
|
128
Chevron
CVX
$382B
| $5.7M | 0.21% |
67,485
+14,110
| +26% | +$1.14M |
|
|
MRTX
129
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $5.69M | 0.21% |
25,918
-20,510
| -44% | -$4.43M |
|
130
MPLX
MPLX
$58.6B
| $5.61M | 0.21% |
258,944
+86,720
| +50% | +$1.71M |
|
131
MaxLinear
MXL
$5.19B
| $5.54M | 0.21% |
145,092
-71,905
| -33% | -$2.09M |
|
132
Lattice Semiconductor
LSCC
$16B
| $5.51M | 0.21% |
+120,305
| New | +$4.65M |
|
|
SWTX
133
DELISTED
SpringWorks Therapeutics
SWTX
| $5.49M | 0.21% |
+75,656
| New | +$4.87M |
|
134
Crocs
CROX
$6.63B
| $5.3M | 0.2% |
84,627
-111,000
| -57% | -$6.34M |
|
135
Enterprise Products Partners
EPD
$83.7B
| $5.21M | 0.19% |
265,756
+75,330
| +40% | +$1.4M |
|
136
Iovance Biotherapeutics
IOVA
$2.04B
| $5.06M | 0.19% |
+109,000
| New | +$4.33M |
|
|
TPIC
137
DELISTED
TPI Composites
TPIC
| $5.05M | 0.19% |
95,604
-118,772
| -55% | -$4.75M |
|
138
Arrowhead Research
ARWR
$12.1B
| $5.03M | 0.19% |
65,490
-14,240
| -18% | -$911K |
|
139
Ameresco
AMRC
$980M
| $4.95M | 0.19% |
94,762
-20,915
| -18% | -$901K |
|
|
OTRK
140
DELISTED
Ontrak
OTRK
| $4.74M | 0.18% |
853
-159
| -16% | -$868K |
|
141
Texas Instruments
TXN
$248B
| $4.46M | 0.17% |
27,150
| – | – |
|
142
Upland Software
UPLD
$13.3M
| $4.44M | 0.17% |
+9,671
| New | +$4.26M |
|
143
Plains All American Pipeline
PAA
$17.6B
| $4.21M | 0.16% |
510,814
+291,590
| +133% | +$2.22M |
|
144
EOG Resources
EOG
$77.7B
| $4.14M | 0.15% |
82,980
| – | – |
|
|
CXO
145
DELISTED
CONCHO RESOURCES INC.
CXO
| $4.09M | 0.15% |
70,110
-140
| -0.2% | -$7.37K |
|
146
Diamondback Energy
FANG
$56B
| $4.06M | 0.15% |
83,963
-250
| -0.3% | -$9.24K |
|
147
Fate Therapeutics
FATE
$275M
| $4.03M | 0.15% |
+44,350
| New | +$2.75M |
|
|
PXD
148
DELISTED
Pioneer Natural Resource Co.
PXD
| $3.85M | 0.14% |
33,794
| – | – |
|
|
PE
149
DELISTED
PARSLEY ENERGY INC
PE
| $3.79M | 0.14% |
266,895
| – | – |
|
150
ConocoPhillips
COP
$144B
| $3.63M | 0.14% |
90,895
+16,170
| +22% | +$596K |
|
Similar funds
MCM
JIC
CFM
SM
TAM
KIA
BGDI
Castleark Management's Q4 2020 Portfolio in Review
As of Q4 2020, Castleark Management held 382 positions worth $2.67B, up 4.7% from $2.55B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Castleark Management withdrew a net $339M in Q4 2020, closing 54 positions and reducing 139 holdings. Its most notable exit was UnitedHealth, an estimated $18.6M position sold in full.
By sector, the portfolio is most concentrated in Technology at 30% of assets, up from 29% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Castleark Management opened a new position in iShares Russell 2000 Value ETF worth $21.9M.
- Castleark Management's largest Q4 2020 buy was iShares Russell 2000 Value ETF: 166,560 shares worth $21.9M.
- Castleark Management added most to Nike in Q4 2020, an estimated $17.4M increase.
- Castleark Management's biggest Q4 2020 reduction was SPDR Gold Trust, cutting an estimated $46.2M.
- Castleark Management fully exited UnitedHealth in Q4 2020, selling an estimated $18.6M.
- Castleark Management's ten largest holdings make up 26% of its $2.67B portfolio in Q4 2020.
- Castleark Management opened 39 new positions and closed 54 in Q4 2020.
- Castleark Management's portfolio value rose 4.7% quarter-over-quarter to $2.67B.
Based on Castleark Management's 13F filing for Q4 2020, filed 17 Feb 2021.